Transplantation· 2018Q1· Guideline
International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients
- 304citations
- Q1SCImago
- 2018year
Short summary
New guidelines from the International Liver Transplantation Society (ILTS) offer expert consensus on managing immunosuppression in liver transplant recipients, aiming to standardize care and improve outcomes.
AI-generated from the title and abstract; the full text is not read.
Key points
- Effective immunosuppression management is critical for optimal liver transplant outcomes.
- Current regimens minimize graft loss but can cause significant toxicities.
- Wide variations in immunosuppression use contribute to outcome disparities between centers.
- The ILTS consensus provides guidelines on induction therapy, rejection treatment, and complication management.
AI-generated from the title and abstract; the full text is not read.
Abstract
In Brief Effective immunosupression management is central to achieving optimal outcomes in liver transplant recipients. Current immunosuppression regimens and agents are highly effective in minimizing graft loss due to acute and chronic rejection but can also produce a substantial array of toxicities. The utilization of immunosuppression varies widely, contributing to the wide disparities in posttransplant outcomes reported between transplant centers. The International Liver Transplantation Society (ILTS) convened a consensus conference, comprised of a global panel of expert hepatologists, transplant surgeons, nephrologists, and pharmacologists to review the literature and experience pertaining to immunosuppression management to develop guidelines on key aspects of immunosuppression. The consensus findings and recommendations of the ILTS Consensus guidelines on immunosuppression in liver transplant recipients are presented in this article. The ILTS consensus document on immunosuppression in liver transplant recipients covers both the scope of therapeutic agents for induction and rejection therapy as well as an overview of complications and clinical management.
The authors' abstract, as published at the source. Transplantation, 2018 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Transplantation
TransplantationMedicine